Advertisement

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

      Abstract

      Background

      Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor–positive, lymph node–negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy.

      Methods

      A retrospective study was performed on 85 consecutive patients with estrogen-receptor–positive, lymph node–negative breast cancer who had an Oncotype DX recurrence score (RS) obtained. Tumor size, tumor grade, and treatment were then compared within each risk category. Statistical analysis was performed using STATA software.

      Results

      Tumors that were high grade and Her-2/neu positive more frequently had a high RS. Treatment was changed as a result of Oncotype DX in 44% of patients.

      Conclusions

      Oncotype DX RS is significantly related to tumor grade and Her2/neu status. In this study, the treatment of 44% of patients was altered as a consequence of Oncotype DX RS.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fisher B.
        • Jeong J.H.
        • Bryant J.
        • et al.
        Treatment of lymph node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
        Lancet. 2004; 364: 858-868
        • Paik S.
        • Tang G.
        • Shak S.
        • et al.
        Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
        J Clin Oncol. 2006; 24: 3726-3734
        • Wolf I.
        • Baruch N.B.
        • Shapira-Frommer R.
        • et al.
        Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients.
        Cancer. 2008; 112: 731-736
        • Paik S.
        • Shak S.
        • Tang G.
        • et al.
        A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
        N Engl J Med. 2004; 351: 2817-2826
        • Lo S.S.
        • Norton J.
        • Mumby P.B.
        • et al.
        Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
        J Clin Oncol. 2007; 25: 577
      1. Erb C, Fox KR, Patel M, et al. Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the Oncotype DX assay at the University of Pennsylvania. Abstract [no. 3082] presented at The 2007 San Antonio Breast Cancer Symposium, San Antonio, TX, December 13 to 16, 2007.